Abstract
Many nanosystems have been prepared and implemented to treat acute kidney injury (AKI). Here, Au@MSN-encapsulated CORM-401 asymmetrical nanocarriers embedded with hyaluronic acid (HA, CD44-targeting agent) was constructed to treat renal tubule injury associated with AKI. The asymmetrical nanosystem could accumulate in the renal injury site through permeability and retention (EPR) behavior. Due to the impactful drug distribution in the kidney combined with the H2O2-responsive CO release, the administration of the asymmetrical nanosystem led to active treatment by nanomotor motion through asymmetrical CO release.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
